Smart Light Therapy Glasses for Sleep and Mental Wellness

NCT ID: NCT07168954

Last Updated: 2025-09-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

96 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-09-03

Study Completion Date

2025-07-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A pair of smart light therapy glasses (Lumos Glasses) was engineered to control the amount of blue light exposure at a person's eyes through a battery powered light source and nano-coating that reflect blue light.

The research aims to study the effects of this pair of light therapy glasses on depression and sleep.

In addition, the research aims to study the effects of duration of use and its correlation with depression and sleep improvements.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Light has a fundamental impact on human biology. Bright light triggers photoreceptors at the back of the retina to induce neurobiological changes in the brain, affecting neurotransmitter levels such as melatonin and cortisol. For those struggling with depression and sleeping disorders, medical professionals generally recommend the use of a light therapy lamp for 30 minutes a day and the patient begins to improve within the first few weeks of use. However, due to the practical limitations of current light therapy devices such as lamps and head gears, longer durations (2 hours or more) of light therapy each day are often considered infeasible for a modern person, and even adherence to 30 minute are low. As such, the correlation of light therapy duration on sleep and mood improvements are not well understood. Due to this hardware limitation, many research efforts aim to study methods to reduce the duration of light therapy for practical benefits, leading to significant limitations and bias in the understanding of light therapy as well as its clinical implications.

From an alternate perspective of understanding, while the intensity of light from a light therapy box (5000 - 10 000 lux) is brighter than average indoor conditions (500 lux), it rarely exceeds the brightness of light from natural outdoors (up to 100 000 lux). And research also suggests that spending time outdoors could be just as effective as a method as light therapy in treating seasonal affective disorder. As such, it is possible that light therapy's role is to make up for a lack of natural light exposure. In this paper, it is hypothesized that the optimal benefits for light therapy can be achieved by simulating light conditions from natural daylight, on average 12 hours of bright light exposure during the day and 12 hours of no light at night. To validate this theory, a consumer friendly light therapy glasses using an innovative nano coating was engineered to allow for full day unencumbered usage.

The Lumos Glasses' nano-coating design is a state of the art advancement in the light therapy wearable space. LED light sources mounted on the side legs (temples) of the glasses project a band of wavelengths of light centred around 480nm (most impactful for neurobiology based on melanopsin response) onto the nano-coating of the glasses, which is designed to reflect only this specific band of light back into the eyes of the user. This design allows the user to be able to see the world through a regular looking pair of glasses while receiving light therapy. The nano-coating, by design, also filters out 480nm band light from the external environment, thus allowing the glasses to be used as blue light blocking glasses in the evenings when the LEDs are off. Due to the geometry of reflection, the light from the glasses enters at an angle of approximately 35 degrees into the user's eyes. This design is unique in that it is able to miss the fovea region of the eye, allowing for less obstructing of vision, while still activating the ganglion cells which are responsible for photobiology.

Because of the unique light delivery method, it is important that the clinical effect of light therapy through the method of angular light delivery through the nano-coating on glasses is validated. The first objective study is to validate the functional effect of the glasses on depression and sleep improvements through a double blind placebo controlled trial.

In the trial, participants are obligated to wear the glasses for 30 minutes a day, however, are strongly recommended to wear it for longer based on the hypothesis above (up to 12 hours during the day following the natural light dark cycle). It is hypothesized that longer durations of usage (matching the natural cycle) would lead to better results. Thus, the second objective of the study is to observe the distribution of adherence and usage time of the glasses in the study population, as well as determine the correlation between average duration of usage and depression and sleep score improvements.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression Sleep Disturbance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The intervention group receives full dose light therapy for the full 8 weeks. The control group receives placebo light therapy from week 1 to week 4, followed by full dose light therapy from week 4 to week 8
Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
Fully blinded study with participants and clinical assessment team blinded. Investigators and outcome assessors access only coded data that masks the interventional after the study to perform analysis.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment group

The treatment group receives fully operational light therapy glasses, with an optimal light output of 500-700 melanopic lux during full power. The users are recommended to wear the glasses for as long as possible during the day, with a minimum requirement of 20 minutes per day. After 8 weeks, this group is cross-overed to receive the placeobo (low dose 50-70 melanopic lux) treatment for another 8 weeks.

Group Type ACTIVE_COMPARATOR

Lumos Glasses

Intervention Type DEVICE

The Lumos Glasses provided tailored blue light therapy and blue light filtering based on the time of day and the user's ambient light conditions. It combines the effect of bright blue light therapy and blue light blocking.

control group

The control group receives placebo operational light therapy glasses, operating at 50-70 melanopic lux during full power. The users are recommended to wear the glasses for as long as possible during the day, with a minimum requirement of 20 minutes per day.

At week 8, the glasses ramp up to the full 500-700 melanopic lux and becomes equivalent to the active comparator group.

Group Type PLACEBO_COMPARATOR

Lumos Glasses

Intervention Type DEVICE

The Lumos Glasses provided tailored blue light therapy and blue light filtering based on the time of day and the user's ambient light conditions. It combines the effect of bright blue light therapy and blue light blocking.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lumos Glasses

The Lumos Glasses provided tailored blue light therapy and blue light filtering based on the time of day and the user's ambient light conditions. It combines the effect of bright blue light therapy and blue light blocking.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Adults, any gender, 18+ years old, residing in Ontario Montgomery Asberg Depression Rating Scale Score \> 7 or PROMIS score \>25 Spend on average less than 2 hours outdoors daily.

Exclusion Criteria

MADRS Score above 45, or MADRS suicide score is 5 or 6 People with eye disorders or previous eye surgeries. People who have cataracts, macular degeneration, diabetic retinopathy, or other eye disorders. People taking light sensitizing medication. People with bipolar, psychotic disorders or a history of these disorders. People with epilepsy, or history of epilepsy. People with electronic implants, such as pacemakers. Prescription glasses wearers, except for people who can self-supply contact Page 6 of 40 lenses for the duration of the study. People who do not have an iOS or Android based smartphone Shift workers who work night shift or rotating shifts with night shifts
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Lumos Health Inc.

UNKNOWN

Sponsor Role collaborator

University of Waterloo

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jonathan M Oakman, Phd, Psychology

Role: PRINCIPAL_INVESTIGATOR

University of Waterloo

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Waterloo

Waterloo, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Related Links

Access external resources that provide additional context or updates about the study.

https://www.lumosglasses.com/

Website of the Lumos Glasses product

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

43406

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Green Light for Post-Operative Wellness
NCT07218289 NOT_YET_RECRUITING NA
Healing Patient Rooms
NCT01504750 COMPLETED NA